Solithera

Morgan Stanley's Andrew Berens downgraded shares of Cempra Inc (NASDAQ: CEMP) to Underweight from Overweight with a price target slashed to $5 from $35 following the U.S. Food and Drug Administration's vote. The FDA's Antimicrobial Disease Advisory Committee voted in favor of Cempra...

JPMorgan’s Jessica Fye believes a key driver for Cempra Inc (NASDAQ: CEMP) will be Solithera, a new antibiotic for community acquired pneumonia (CABP) in adults. Fye initiated coverage of the company with an Overweight rating and price target of $31. Potential For Solithera “With the...